Your browser is no longer supported. Please, upgrade your browser.
MGTA Magenta Therapeutics, Inc. daily Stock Chart
Magenta Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.62 Insider Own14.47% Shs Outstand26.27M Perf Week7.34%
Market Cap487.83M Forward P/E- EPS next Y-2.31 Insider Trans- Shs Float26.27M Perf Month114.19%
Income- PEG- EPS next Q-0.56 Inst Own56.50% Short Float5.63% Perf Quarter208.47%
Sales- P/S- EPS this Y-264.70% Inst Trans133.39% Short Ratio8.40 Perf Half Y60.09%
Book/sh4.84 P/B3.84 EPS next Y51.50% ROA- Target Price20.33 Perf Year-
Cash/sh6.08 P/C3.05 EPS next 5Y- ROE- 52W Range5.31 - 19.74 Perf YTD225.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.92% Beta-
Dividend %- Quick Ratio13.70 Sales past 5Y- Gross Margin- 52W Low249.72% ATR1.67
Employees48 Current Ratio13.70 Sales Q/Q- Oper. Margin- RSI (14)73.59 Volatility10.54% 12.89%
OptionableNo Debt/Eq0.00 EPS Q/Q-223.00% Profit Margin- Rel Volume2.10 Prev Close18.28
ShortableYes LT Debt/Eq0.00 EarningsFeb 28 Payout- Avg Volume175.85K Price18.57
Recom1.80 SMA2022.96% SMA5077.90% SMA20073.22% Volume368,936 Change1.59%
Mar-15-19Initiated Raymond James Outperform
Jul-16-18Initiated Wedbush Outperform $22
Jul-16-18Initiated JP Morgan Overweight $18
Jul-16-18Initiated Goldman Buy $18
Mar-20-19 12:07PM  Raymond James Thinks Magenta Still Has Upside
Mar-19-19 07:30AM  Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights Business Wire
Mar-15-19 01:32PM  How Many Insiders Bought Magenta Therapeutics, Inc. (NASDAQ:MGTA) Shares? Simply Wall St. +26.19%
Mar-06-19 04:05PM  Magenta Therapeutics to Present at Investor Conferences in March Business Wire
Feb-25-19 08:15AM  Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate Business Wire +12.03%
08:15AM  Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting Business Wire
Feb-21-19 08:00AM  Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant Business Wire -5.66%
Feb-07-19 08:30AM  Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference Business Wire
Jan-02-19 08:30AM  Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 Business Wire +5.26%
Dec-02-18 09:00PM  Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit Business Wire
09:00PM  Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders Business Wire
Dec-01-18 12:30PM  Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate Business Wire
Nov-26-18 08:30AM  Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH Business Wire
Nov-19-18 08:00AM  Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer Business Wire
Nov-08-18 08:00AM  Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results Business Wire
Nov-01-18 09:00AM  Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expansion Programs Business Wire -5.82%
Sep-24-18 08:30AM  Magenta Therapeutics Added to Russell 2000 and 3000 Indexes Business Wire +5.92%
Aug-09-18 04:05PM  Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results Business Wire
Aug-08-18 04:05PM  Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference Business Wire
Jul-25-18 07:40AM  Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-16-18 12:33PM  Wedbush Bets On Magenta Therapeutics, Projects Rewards If Stem Cell Technology Successful Benzinga
Jul-03-18 06:23AM  Goodwin dominates this years record batch of Mass. biotech IPOs American City Business Journals
Jun-25-18 04:05PM  Magenta Therapeutics Announces Closing of Initial Public Offering Business Wire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 10:01PM  [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry The Wall Street Journal
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
Jun-18-18 01:36PM  Don't Fear This Burst of Biotech IPOs Bloomberg
Jun-17-18 04:22PM  The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma Benzinga
Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.